Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Гипотермия кожи головы для профилактики алопеции, индуцированной химиотерапией при раке молочной железы
Гипотермия кожи головы для профилактики алопеции, индуцированной химиотерапией при раке молочной железы
Огнерубов Н. А., Барсуков С. В. Гипотермия кожи головы для профилактики алопеции, индуцированной химиотерапией при раке молочной железы. Современная Онкология. 2023;25(4):513–517.
DOI: 10.26442/18151434.2023.4.202549
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
DOI: 10.26442/18151434.2023.4.202549
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Обоснование. Рак молочной железы (РМЖ) представляет социально значимое заболевание у женщин в мире, занимая 1‑е место в структуре заболеваемости и 5‑е по числу смертей. На долю полихимиотерапии среди специальных методов лечения РМЖ приходится примерно 80%. Основным побочным эффектом, значительно влияющим на качество жизни, является алопеция, которая в среднем наблюдается в 65% случаев.
Цель. Оценить эффективность и переносимость гипотермии кожи головы (ГТКГ) для профилактики алопеции, индуцированной химиотерапией у больных РМЖ.
Материалы и методы. С июня 2016 по сентябрь 2023 г. под наблюдением находились 75 больных РМЖ I–IV стадии, медиана возраста – 44,1 года. Всем пациентам проводилась цитотоксическая терапия на различных этапах лечения. Для профилактики алопеции применяли локальную ГТКГ с помощью аппарата Orbis II (Paxman Coolers, Великобритания).
Результаты. I стадия опухолевого процесса наблюдалась у 18 (24%) пациентов, II – у 22 (29,3%), III – у 30 (40%), IV – у 5 (6,7%). Больные получали 5 различных режимов полихимиотерапии в нео- и адъювантном вариантах. Среди них преобладали таксансодержащие комбинированные схемы. Проведено 364 сеанса ГТКГ пациентов (4–8 сеансов у каждого), в полном объеме процедуру получили 48 (64%) больных. Полное сохранение волос отмечено у 43 (57,3%) пациентов. Чаще наблюдалась алопеция 1‑й степени – у 19 (25,4%), а 2‑й степени – у 9 (12%) человек. Из 5 больных диссеминированным РМЖ алопеция 2‑й степени констатирована у 1 пациентки, 3‑й степени – у 3, а 4‑й степени – у 1. Побочные эффекты наблюдались у 16% пролеченных больных. Среди них чаще всего отмечались ощущение холода и легкая головная боль. Из-за непереносимости холодового шлема 3 пациента отказались от его применения. За время наблюдения метастазов рака в кожу головы не выявлено. Во время процедуры практически все пациенты отмечали высокий уровень комфорта.
Заключение. Локальная ГТКГ – эффективный метод профилактики алопеции, индуцированной цитотоксической терапией у больных РМЖ. Это позволяет повысить психологическую и социальную адаптацию пациентов.
Ключевые слова: рак молочной железы, химиотерапия, алопеция, профилактика, гипотермия
Aim. To evaluate the efficacy and tolerability of scalp hypothermia (SHT) for the prevention of chemotherapy-induced alopecia in patients with BC.
Materials and methods. From June 2016 to September 2023, 75 patients with a median age of 44.1 years with stage I–IV BC were observed. All patients received cytotoxic therapy at various stages of treatment. To prevent alopecia, local SHT was used using an Orbis II device (Paxman Coolers, United Kingdom).
Results. Stage I of the disease was observed in 18 (24%) patients, stage II in 22 (29.3%), stage III in 30 (40%), and stage IV in 5 (6.7%). Patients received 5 different neo- and adjuvant regimens of polychemotherapy. Taxane-containing combined regimens prevailed. 364 SHT sessions (4–8 sessions per patient) were performed; 48 (64%) patients received the procedure in full. Complete hair preservation was achieved in 43 (57.3%) patients. Grade 1 alopecia was observed in 19 (25.4%) patients and grade 2 in 9 (12%) patients. Of the 5 patients with advanced BC, grade 2 alopecia was reported in 1 patient, grade 3 in 3, and grade 4 in 1. Side effects were reported in 16% of cases; the most common were a feeling of cold and a slight headache. Due to the intolerance of the cold helmet, 3 patients refused to use it. No scalp metastases were observed during the follow-up. During the procedure, almost all patients noted a high level of comfort.
Conclusion. Local SHT is an effective method of preventing cytotoxic therapy-induced alopecia in patients with BC. It improves the psychological and social adaptation of patients.
Keywords: breast cancer, chemotherapy, alopecia, prevention, hypothermia
Цель. Оценить эффективность и переносимость гипотермии кожи головы (ГТКГ) для профилактики алопеции, индуцированной химиотерапией у больных РМЖ.
Материалы и методы. С июня 2016 по сентябрь 2023 г. под наблюдением находились 75 больных РМЖ I–IV стадии, медиана возраста – 44,1 года. Всем пациентам проводилась цитотоксическая терапия на различных этапах лечения. Для профилактики алопеции применяли локальную ГТКГ с помощью аппарата Orbis II (Paxman Coolers, Великобритания).
Результаты. I стадия опухолевого процесса наблюдалась у 18 (24%) пациентов, II – у 22 (29,3%), III – у 30 (40%), IV – у 5 (6,7%). Больные получали 5 различных режимов полихимиотерапии в нео- и адъювантном вариантах. Среди них преобладали таксансодержащие комбинированные схемы. Проведено 364 сеанса ГТКГ пациентов (4–8 сеансов у каждого), в полном объеме процедуру получили 48 (64%) больных. Полное сохранение волос отмечено у 43 (57,3%) пациентов. Чаще наблюдалась алопеция 1‑й степени – у 19 (25,4%), а 2‑й степени – у 9 (12%) человек. Из 5 больных диссеминированным РМЖ алопеция 2‑й степени констатирована у 1 пациентки, 3‑й степени – у 3, а 4‑й степени – у 1. Побочные эффекты наблюдались у 16% пролеченных больных. Среди них чаще всего отмечались ощущение холода и легкая головная боль. Из-за непереносимости холодового шлема 3 пациента отказались от его применения. За время наблюдения метастазов рака в кожу головы не выявлено. Во время процедуры практически все пациенты отмечали высокий уровень комфорта.
Заключение. Локальная ГТКГ – эффективный метод профилактики алопеции, индуцированной цитотоксической терапией у больных РМЖ. Это позволяет повысить психологическую и социальную адаптацию пациентов.
Ключевые слова: рак молочной железы, химиотерапия, алопеция, профилактика, гипотермия
________________________________________________
Aim. To evaluate the efficacy and tolerability of scalp hypothermia (SHT) for the prevention of chemotherapy-induced alopecia in patients with BC.
Materials and methods. From June 2016 to September 2023, 75 patients with a median age of 44.1 years with stage I–IV BC were observed. All patients received cytotoxic therapy at various stages of treatment. To prevent alopecia, local SHT was used using an Orbis II device (Paxman Coolers, United Kingdom).
Results. Stage I of the disease was observed in 18 (24%) patients, stage II in 22 (29.3%), stage III in 30 (40%), and stage IV in 5 (6.7%). Patients received 5 different neo- and adjuvant regimens of polychemotherapy. Taxane-containing combined regimens prevailed. 364 SHT sessions (4–8 sessions per patient) were performed; 48 (64%) patients received the procedure in full. Complete hair preservation was achieved in 43 (57.3%) patients. Grade 1 alopecia was observed in 19 (25.4%) patients and grade 2 in 9 (12%) patients. Of the 5 patients with advanced BC, grade 2 alopecia was reported in 1 patient, grade 3 in 3, and grade 4 in 1. Side effects were reported in 16% of cases; the most common were a feeling of cold and a slight headache. Due to the intolerance of the cold helmet, 3 patients refused to use it. No scalp metastases were observed during the follow-up. During the procedure, almost all patients noted a high level of comfort.
Conclusion. Local SHT is an effective method of preventing cytotoxic therapy-induced alopecia in patients with BC. It improves the psychological and social adaptation of patients.
Keywords: breast cancer, chemotherapy, alopecia, prevention, hypothermia
Полный текст
Список литературы
1. Kiebert GM, Hanneke J, de Haes CJ, et al. Effect of peri-operative chemotherapy on the quality of life of patients with early breast cancer. Eur J Cancer. 1990;26(10):1038‑42. DOI:10.1016/0277‑5379(90)90046‑v
2. Lemieux J, Maunsell E, Provencher L. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: A literature review. Psychooncology. 2008;17(4):317‑28. DOI:10.1002/pon.1245
3. Trüeb RM. Chemotherapy-induced alopecia. Curr Opin Support Palliat Care. 2010;4(4):281‑4. DOI:10.1097/SPC.0b013e3283409280
4. Choi EK, Kim IR, Chang O, et al. Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients. Psychooncology. 2014;23(10):1103‑10. DOI:10.1002/pon.3531
5. Dorr VJ. A practitioner’s guide to cancer-related alopecia. Semin Oncol. 1998;25(5):562‑70. PMID:9783595
6. Auvinen PK, Mähönen UA, Soininen KM, et al. The effectiveness of a scalp cooling cap in preventing chemotherapy-induced alopecia. Tumori. 2010;96(2):271‑5. DOI:10.1177/030089161009600214
7. Hussein AM. Chemotherapy-induced alopecia: new developments. South Med J. 1993;86(5):489‑96. DOI:10.1097/00007611‑199305000‑00001
8. McGarvey EL, Baum LD, Pinkerton RC, Rogers LM. Psychological sequelae and alopecia among women with cancer. Cancer Pract. 2001;9(6):283‑9. DOI:10.1046/j.1523‑5394.2001.96007.x
9. Trüeb RM. Chemotherapy-induced hair loss. Skin Therapy Lett. 2010;15(7):5‑7. PMID: 20700552
10. Mols F, van den Hurk CJ, Vingerhoets AJ, Breed WP. Scalp cooling to prevent chemotherapy-induced hair loss: Practical and clinical considerations. Support Care Cancer. 2009;17(2):181‑9. DOI:10.1007/s00520‑008‑0475‑4
11. Paus R, Haslam IS, Sharov AA, Botchkarev VA. Pathobiology of chemotherapy-induced hair loss. Lancet Oncol. 2013;14(2):e50‑9. DOI:10.1016/S1470‑2045(12)70553‑3
12. Kang D, Kim IR, Choi EK, et al. Permanent chemotherapy-induced alopecia in patients with breast cancer: A 3‑year prospective cohort study. Oncologist. 2019;24(3):414‑20. DOI:10.1634/theoncologist.2018‑0184
13. Dunnill CJ, Al-Tameemi W, Collett A, et al. A clinical and biological guide for understanding chemotherapy-induced alopecia and its prevention. Oncologist. 2018;23(1):84‑96. DOI:10.1634/theoncologist.2017‑0263
14. Shin H, Jo SJ, Kim DH, et al. Efficacy of interventions for prevention of chemotherapy-induced alopecia: A systematic review and meta-analysis. Int J Cancer. 2015;136(5): E442‑54. DOI:10.1002/ijc.29115
15. Chon SY, Champion RW, Geddes ER, Rashid RM. Chemotherapy-induced alopecia. J Am Acad Dermatol. 2012;67(1):e37‑47. DOI:10.1016/j.jaad.2011.02.026
16. Rossi A, Caterina Fortuna M, Caro G, et al. Monitoring chemotherapy-induced alopecia with trichoscopy. J Cosmet Dermatol. 2019;18(2):575‑80. DOI:10.1111/jocd.12687
17. Freites-Martinez A, Shapiro J, Goldfarb S, et al. Hair disorders in patients with cancer. J Am Acad Dermatol. 2019;80(5):1179‑96. DOI:10.1016/j.jaad.2018.03.055
18. Haider M, Hamadah I, Almutawa A. Radiation- and chemotherapy-induced permanent alopecia: Case series. J Cutan Med Surg. 2013;17(1):55‑61. DOI:10.2310/7750.2012.12033
19. Skrok A, Bednarczuk T, Skwarek A, et al. The effect of parathyroid hormones on hair follicle physiology: Implications for treatment of chemotherapy-induced alopecia. Skin Pharmacol Physiol. 2015;28(4):213‑25. DOI:10.1159/000375319
20. Katikaneni R, Ponnapakkam T, Matsushita O, et al. Treatment and prevention of chemotherapy-induced alopecia with PTH-CBD, a collagen-targeted parathyroid hormone analog, in a non-depilated mouse model. Anticancer Drugs. 2014;25(1):30‑8. DOI:10.1097/CAD.0b013e3283650bff
21. Rugo HS, Klein P, Melin SA, et al. Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. JAMA. 2017;317(6):606‑14. DOI:10.1001/jama.2016.21038
22. Nangia J, Wang T, Osborne C, et al. Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: The SCALP randomized clinical trial. JAMA. 2017;317(6):596‑605. DOI:10.1001/jama.2016.20939
23. Trujillo-Martín MM, de Armas-Castellano A, González-Hernández Y, et al. Enfriamiento del cuero cabelludo para la prevención de la alopecia secundaria a quimioterapia: Revisión sistemática y metanálisis. Rev Esp Salud Publica. 2023;97:e202303024 (in Spanish). PMID:36999663
24. Rugo HS, Voigt J. Scalp hypothermia for preventing alopecia during chemotherapy. A systematic review and meta-analysis of randomized controlled trials. Clin Breast Cancer. 2018;18(1):19‑28. DOI:10.1016/j.clbc.2017.07.012
25. Lacouture ME, Sibaud V, Gerber PA, et al.; ESMO Guidelines Committee. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines. Ann Oncol. 2021;32(2):157‑70. DOI:10.1016/j.annonc.2020.11.005
26. Cho J, Choi EK, Kim IR, et al. Development and validation of Chemotherapy-induced Alopecia Distress Scale (CADS) for breast cancer patients. Ann Oncol. 2014;25(2):346‑51. DOI:10.1093/annonc/mdt476
27. Wilson BE, Jacob S, Yap ML, et al. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: A population-based study. Lancet Oncol. 2019;20(6):769‑80. DOI:10.1016/S1470‑2045(19)30163‑9
28. Gandhi M, Oishi K, Zubal B, Lacouture ME. Unanticipated toxicities from anticancer therapies: Survivors’ perspectives. Support Care Cancer. 2010;18(11):1461‑8. DOI:10.1007/s00520‑009‑0769‑1
29. Paterson C, Kozlovskaia M, Turner M, et al. Identifying the supportive care needs of men and women affected by chemotherapy-induced alopecia? A systematic review. J Cancer Surviv. 2021;15(1):14‑28. DOI:10.1007/s11764‑020‑00907‑6
30. Станоевич И.В., Хвостовой В.В., Тишина Е. И., и др. Алопеция в онкологии: практическое значение фундаментальных исследований. Сибирский онкологический журнал. 2023;22(1):128‑40 [Stanoevich IV, Khvostovoy VV, Tishina EI, et al. Alopecia in oncology: The practical significance of fundamental research. Siberian Journal of Oncology. 2023;22(1):128‑40 (in Russian)]. DOI:10.21294/1814‑4861‑2023‑22‑1–128‑140
31. Kanti V, Nuwayhid R, Lindner J, et al. Analysis of quantitative changes in hair growth during treatment with chemotherapy or tamoxifen in patients with breast cancer: A cohort study. Br J Dermatol. 2014;170(3):643‑50. DOI:10.1111/bjd.12716
32. Chan J, Adderley H, Alameddine M, et al. Permanent hair loss associated with taxane chemotherapy use in breast cancer: A retrospective survey at two tertiary UK cancer centres. Eur J Cancer Care (Engl). 2021;30(3):e13395. DOI:10.1111/ecc.13395
33. Bhoyrul B, Asfour L, Lutz G, et al. Clinicopathologic characteristics and response to treatment of persistent chemotherapy-induced alopecia in breast cancer survivors. JAMA Dermatol. 2021;157(11):1335‑42. DOI:10.1001/jamadermatol.2021.3676
34. Freites-Martinez A, Shapiro J, Chan D, et al. Endocrine therapy-induced alopecia in patients with breast cancer. JAMA Dermatol. 2018;154(6):670‑5. DOI:10.1001/jamadermatol.2018.0454
35. Gallicchio L, Calhoun C, Helzlsouer KJ. Aromatase inhibitor therapy and hair loss among breast cancer survivors. Breast Cancer Res Treat. 2013;142(2):435‑43. DOI:10.1007/s10549‑013‑2744‑2
36. Rugo HS, van den Hurk C. Alopecia related to systemic cancer therapy. 2023. Available at: https://www.uptodate.com/contents/alopecia-related-to-systemic-cancer-therapy/print. Accessed: 05.09.2023.
37. Shah VV, Wikramanayake TC, DelCanto GM, et al. Scalp hypothermia as a preventative measure for chemotherapy-induced alopecia: A review of controlled clinical trials. J Eur Acad Dermatol Venereol. 2018;32(5):720‑34. DOI:10.1111/jdv.14612
38. Belum VR, de Barros Silva G, Laloni MT, et al. Cold thermal injury from cold caps used for the prevention of chemotherapy-induced alopecia. Breast Cancer Res Treat. 2016;157(2):395‑400. DOI:10.1007/s10549‑016‑3799‑7
39. Smetanay K, Junio P, Feißt M, et al. COOLHAIR: A prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer. Breast Cancer Res Treat. 2019;173(1):135‑43. DOI:10.1007/s10549‑018‑4983‑8
40. Bajpai J, Kagwade S, Chandrasekharan A, et al. Randomised controlled trial of scalp cooling for the prevention of chemotherapy induced alopecia. Breast. 2020;49:187‑93. DOI:10.1016/j.breast.2019.12.004
41. NCCN Clinical Practice Guidelines in Oncology. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx#site. Accessed: 04.11.2019.
2. Lemieux J, Maunsell E, Provencher L. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: A literature review. Psychooncology. 2008;17(4):317‑28. DOI:10.1002/pon.1245
3. Trüeb RM. Chemotherapy-induced alopecia. Curr Opin Support Palliat Care. 2010;4(4):281‑4. DOI:10.1097/SPC.0b013e3283409280
4. Choi EK, Kim IR, Chang O, et al. Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients. Psychooncology. 2014;23(10):1103‑10. DOI:10.1002/pon.3531
5. Dorr VJ. A practitioner’s guide to cancer-related alopecia. Semin Oncol. 1998;25(5):562‑70. PMID:9783595
6. Auvinen PK, Mähönen UA, Soininen KM, et al. The effectiveness of a scalp cooling cap in preventing chemotherapy-induced alopecia. Tumori. 2010;96(2):271‑5. DOI:10.1177/030089161009600214
7. Hussein AM. Chemotherapy-induced alopecia: new developments. South Med J. 1993;86(5):489‑96. DOI:10.1097/00007611‑199305000‑00001
8. McGarvey EL, Baum LD, Pinkerton RC, Rogers LM. Psychological sequelae and alopecia among women with cancer. Cancer Pract. 2001;9(6):283‑9. DOI:10.1046/j.1523‑5394.2001.96007.x
9. Trüeb RM. Chemotherapy-induced hair loss. Skin Therapy Lett. 2010;15(7):5‑7. PMID: 20700552
10. Mols F, van den Hurk CJ, Vingerhoets AJ, Breed WP. Scalp cooling to prevent chemotherapy-induced hair loss: Practical and clinical considerations. Support Care Cancer. 2009;17(2):181‑9. DOI:10.1007/s00520‑008‑0475‑4
11. Paus R, Haslam IS, Sharov AA, Botchkarev VA. Pathobiology of chemotherapy-induced hair loss. Lancet Oncol. 2013;14(2):e50‑9. DOI:10.1016/S1470‑2045(12)70553‑3
12. Kang D, Kim IR, Choi EK, et al. Permanent chemotherapy-induced alopecia in patients with breast cancer: A 3‑year prospective cohort study. Oncologist. 2019;24(3):414‑20. DOI:10.1634/theoncologist.2018‑0184
13. Dunnill CJ, Al-Tameemi W, Collett A, et al. A clinical and biological guide for understanding chemotherapy-induced alopecia and its prevention. Oncologist. 2018;23(1):84‑96. DOI:10.1634/theoncologist.2017‑0263
14. Shin H, Jo SJ, Kim DH, et al. Efficacy of interventions for prevention of chemotherapy-induced alopecia: A systematic review and meta-analysis. Int J Cancer. 2015;136(5): E442‑54. DOI:10.1002/ijc.29115
15. Chon SY, Champion RW, Geddes ER, Rashid RM. Chemotherapy-induced alopecia. J Am Acad Dermatol. 2012;67(1):e37‑47. DOI:10.1016/j.jaad.2011.02.026
16. Rossi A, Caterina Fortuna M, Caro G, et al. Monitoring chemotherapy-induced alopecia with trichoscopy. J Cosmet Dermatol. 2019;18(2):575‑80. DOI:10.1111/jocd.12687
17. Freites-Martinez A, Shapiro J, Goldfarb S, et al. Hair disorders in patients with cancer. J Am Acad Dermatol. 2019;80(5):1179‑96. DOI:10.1016/j.jaad.2018.03.055
18. Haider M, Hamadah I, Almutawa A. Radiation- and chemotherapy-induced permanent alopecia: Case series. J Cutan Med Surg. 2013;17(1):55‑61. DOI:10.2310/7750.2012.12033
19. Skrok A, Bednarczuk T, Skwarek A, et al. The effect of parathyroid hormones on hair follicle physiology: Implications for treatment of chemotherapy-induced alopecia. Skin Pharmacol Physiol. 2015;28(4):213‑25. DOI:10.1159/000375319
20. Katikaneni R, Ponnapakkam T, Matsushita O, et al. Treatment and prevention of chemotherapy-induced alopecia with PTH-CBD, a collagen-targeted parathyroid hormone analog, in a non-depilated mouse model. Anticancer Drugs. 2014;25(1):30‑8. DOI:10.1097/CAD.0b013e3283650bff
21. Rugo HS, Klein P, Melin SA, et al. Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. JAMA. 2017;317(6):606‑14. DOI:10.1001/jama.2016.21038
22. Nangia J, Wang T, Osborne C, et al. Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: The SCALP randomized clinical trial. JAMA. 2017;317(6):596‑605. DOI:10.1001/jama.2016.20939
23. Trujillo-Martín MM, de Armas-Castellano A, González-Hernández Y, et al. Enfriamiento del cuero cabelludo para la prevención de la alopecia secundaria a quimioterapia: Revisión sistemática y metanálisis. Rev Esp Salud Publica. 2023;97:e202303024 (in Spanish). PMID:36999663
24. Rugo HS, Voigt J. Scalp hypothermia for preventing alopecia during chemotherapy. A systematic review and meta-analysis of randomized controlled trials. Clin Breast Cancer. 2018;18(1):19‑28. DOI:10.1016/j.clbc.2017.07.012
25. Lacouture ME, Sibaud V, Gerber PA, et al.; ESMO Guidelines Committee. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines. Ann Oncol. 2021;32(2):157‑70. DOI:10.1016/j.annonc.2020.11.005
26. Cho J, Choi EK, Kim IR, et al. Development and validation of Chemotherapy-induced Alopecia Distress Scale (CADS) for breast cancer patients. Ann Oncol. 2014;25(2):346‑51. DOI:10.1093/annonc/mdt476
27. Wilson BE, Jacob S, Yap ML, et al. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: A population-based study. Lancet Oncol. 2019;20(6):769‑80. DOI:10.1016/S1470‑2045(19)30163‑9
28. Gandhi M, Oishi K, Zubal B, Lacouture ME. Unanticipated toxicities from anticancer therapies: Survivors’ perspectives. Support Care Cancer. 2010;18(11):1461‑8. DOI:10.1007/s00520‑009‑0769‑1
29. Paterson C, Kozlovskaia M, Turner M, et al. Identifying the supportive care needs of men and women affected by chemotherapy-induced alopecia? A systematic review. J Cancer Surviv. 2021;15(1):14‑28. DOI:10.1007/s11764‑020‑00907‑6
30. Stanoevich IV, Khvostovoy VV, Tishina EI, et al. Alopecia in oncology: The practical significance of fundamental research. Siberian Journal of Oncology. 2023;22(1):128‑40 (in Russian). DOI:10.21294/1814‑4861‑2023‑22‑1–128‑140
31. Kanti V, Nuwayhid R, Lindner J, et al. Analysis of quantitative changes in hair growth during treatment with chemotherapy or tamoxifen in patients with breast cancer: A cohort study. Br J Dermatol. 2014;170(3):643‑50. DOI:10.1111/bjd.12716
32. Chan J, Adderley H, Alameddine M, et al. Permanent hair loss associated with taxane chemotherapy use in breast cancer: A retrospective survey at two tertiary UK cancer centres. Eur J Cancer Care (Engl). 2021;30(3):e13395. DOI:10.1111/ecc.13395
33. Bhoyrul B, Asfour L, Lutz G, et al. Clinicopathologic characteristics and response to treatment of persistent chemotherapy-induced alopecia in breast cancer survivors. JAMA Dermatol. 2021;157(11):1335‑42. DOI:10.1001/jamadermatol.2021.3676
34. Freites-Martinez A, Shapiro J, Chan D, et al. Endocrine therapy-induced alopecia in patients with breast cancer. JAMA Dermatol. 2018;154(6):670‑5. DOI:10.1001/jamadermatol.2018.0454
35. Gallicchio L, Calhoun C, Helzlsouer KJ. Aromatase inhibitor therapy and hair loss among breast cancer survivors. Breast Cancer Res Treat. 2013;142(2):435‑43. DOI:10.1007/s10549‑013‑2744‑2
36. Rugo HS, van den Hurk C. Alopecia related to systemic cancer therapy. 2023. Available at: https://www.uptodate.com/contents/alopecia-related-to-systemic-cancer-therapy/print. Accessed: 05.09.2023.
37. Shah VV, Wikramanayake TC, DelCanto GM, et al. Scalp hypothermia as a preventative measure for chemotherapy-induced alopecia: A review of controlled clinical trials. J Eur Acad Dermatol Venereol. 2018;32(5):720‑34. DOI:10.1111/jdv.14612
38. Belum VR, de Barros Silva G, Laloni MT, et al. Cold thermal injury from cold caps used for the prevention of chemotherapy-induced alopecia. Breast Cancer Res Treat. 2016;157(2):395‑400. DOI:10.1007/s10549‑016‑3799‑7
39. Smetanay K, Junio P, Feißt M, et al. COOLHAIR: A prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer. Breast Cancer Res Treat. 2019;173(1):135‑43. DOI:10.1007/s10549‑018‑4983‑8
40. Bajpai J, Kagwade S, Chandrasekharan A, et al. Randomised controlled trial of scalp cooling for the prevention of chemotherapy induced alopecia. Breast. 2020;49:187‑93. DOI:10.1016/j.breast.2019.12.004
41. NCCN Clinical Practice Guidelines in Oncology. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx#site. Accessed: 04.11.2019.
2. Lemieux J, Maunsell E, Provencher L. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: A literature review. Psychooncology. 2008;17(4):317‑28. DOI:10.1002/pon.1245
3. Trüeb RM. Chemotherapy-induced alopecia. Curr Opin Support Palliat Care. 2010;4(4):281‑4. DOI:10.1097/SPC.0b013e3283409280
4. Choi EK, Kim IR, Chang O, et al. Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients. Psychooncology. 2014;23(10):1103‑10. DOI:10.1002/pon.3531
5. Dorr VJ. A practitioner’s guide to cancer-related alopecia. Semin Oncol. 1998;25(5):562‑70. PMID:9783595
6. Auvinen PK, Mähönen UA, Soininen KM, et al. The effectiveness of a scalp cooling cap in preventing chemotherapy-induced alopecia. Tumori. 2010;96(2):271‑5. DOI:10.1177/030089161009600214
7. Hussein AM. Chemotherapy-induced alopecia: new developments. South Med J. 1993;86(5):489‑96. DOI:10.1097/00007611‑199305000‑00001
8. McGarvey EL, Baum LD, Pinkerton RC, Rogers LM. Psychological sequelae and alopecia among women with cancer. Cancer Pract. 2001;9(6):283‑9. DOI:10.1046/j.1523‑5394.2001.96007.x
9. Trüeb RM. Chemotherapy-induced hair loss. Skin Therapy Lett. 2010;15(7):5‑7. PMID: 20700552
10. Mols F, van den Hurk CJ, Vingerhoets AJ, Breed WP. Scalp cooling to prevent chemotherapy-induced hair loss: Practical and clinical considerations. Support Care Cancer. 2009;17(2):181‑9. DOI:10.1007/s00520‑008‑0475‑4
11. Paus R, Haslam IS, Sharov AA, Botchkarev VA. Pathobiology of chemotherapy-induced hair loss. Lancet Oncol. 2013;14(2):e50‑9. DOI:10.1016/S1470‑2045(12)70553‑3
12. Kang D, Kim IR, Choi EK, et al. Permanent chemotherapy-induced alopecia in patients with breast cancer: A 3‑year prospective cohort study. Oncologist. 2019;24(3):414‑20. DOI:10.1634/theoncologist.2018‑0184
13. Dunnill CJ, Al-Tameemi W, Collett A, et al. A clinical and biological guide for understanding chemotherapy-induced alopecia and its prevention. Oncologist. 2018;23(1):84‑96. DOI:10.1634/theoncologist.2017‑0263
14. Shin H, Jo SJ, Kim DH, et al. Efficacy of interventions for prevention of chemotherapy-induced alopecia: A systematic review and meta-analysis. Int J Cancer. 2015;136(5): E442‑54. DOI:10.1002/ijc.29115
15. Chon SY, Champion RW, Geddes ER, Rashid RM. Chemotherapy-induced alopecia. J Am Acad Dermatol. 2012;67(1):e37‑47. DOI:10.1016/j.jaad.2011.02.026
16. Rossi A, Caterina Fortuna M, Caro G, et al. Monitoring chemotherapy-induced alopecia with trichoscopy. J Cosmet Dermatol. 2019;18(2):575‑80. DOI:10.1111/jocd.12687
17. Freites-Martinez A, Shapiro J, Goldfarb S, et al. Hair disorders in patients with cancer. J Am Acad Dermatol. 2019;80(5):1179‑96. DOI:10.1016/j.jaad.2018.03.055
18. Haider M, Hamadah I, Almutawa A. Radiation- and chemotherapy-induced permanent alopecia: Case series. J Cutan Med Surg. 2013;17(1):55‑61. DOI:10.2310/7750.2012.12033
19. Skrok A, Bednarczuk T, Skwarek A, et al. The effect of parathyroid hormones on hair follicle physiology: Implications for treatment of chemotherapy-induced alopecia. Skin Pharmacol Physiol. 2015;28(4):213‑25. DOI:10.1159/000375319
20. Katikaneni R, Ponnapakkam T, Matsushita O, et al. Treatment and prevention of chemotherapy-induced alopecia with PTH-CBD, a collagen-targeted parathyroid hormone analog, in a non-depilated mouse model. Anticancer Drugs. 2014;25(1):30‑8. DOI:10.1097/CAD.0b013e3283650bff
21. Rugo HS, Klein P, Melin SA, et al. Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. JAMA. 2017;317(6):606‑14. DOI:10.1001/jama.2016.21038
22. Nangia J, Wang T, Osborne C, et al. Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: The SCALP randomized clinical trial. JAMA. 2017;317(6):596‑605. DOI:10.1001/jama.2016.20939
23. Trujillo-Martín MM, de Armas-Castellano A, González-Hernández Y, et al. Enfriamiento del cuero cabelludo para la prevención de la alopecia secundaria a quimioterapia: Revisión sistemática y metanálisis. Rev Esp Salud Publica. 2023;97:e202303024 (in Spanish). PMID:36999663
24. Rugo HS, Voigt J. Scalp hypothermia for preventing alopecia during chemotherapy. A systematic review and meta-analysis of randomized controlled trials. Clin Breast Cancer. 2018;18(1):19‑28. DOI:10.1016/j.clbc.2017.07.012
25. Lacouture ME, Sibaud V, Gerber PA, et al.; ESMO Guidelines Committee. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines. Ann Oncol. 2021;32(2):157‑70. DOI:10.1016/j.annonc.2020.11.005
26. Cho J, Choi EK, Kim IR, et al. Development and validation of Chemotherapy-induced Alopecia Distress Scale (CADS) for breast cancer patients. Ann Oncol. 2014;25(2):346‑51. DOI:10.1093/annonc/mdt476
27. Wilson BE, Jacob S, Yap ML, et al. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: A population-based study. Lancet Oncol. 2019;20(6):769‑80. DOI:10.1016/S1470‑2045(19)30163‑9
28. Gandhi M, Oishi K, Zubal B, Lacouture ME. Unanticipated toxicities from anticancer therapies: Survivors’ perspectives. Support Care Cancer. 2010;18(11):1461‑8. DOI:10.1007/s00520‑009‑0769‑1
29. Paterson C, Kozlovskaia M, Turner M, et al. Identifying the supportive care needs of men and women affected by chemotherapy-induced alopecia? A systematic review. J Cancer Surviv. 2021;15(1):14‑28. DOI:10.1007/s11764‑020‑00907‑6
30. Станоевич И.В., Хвостовой В.В., Тишина Е. И., и др. Алопеция в онкологии: практическое значение фундаментальных исследований. Сибирский онкологический журнал. 2023;22(1):128‑40 [Stanoevich IV, Khvostovoy VV, Tishina EI, et al. Alopecia in oncology: The practical significance of fundamental research. Siberian Journal of Oncology. 2023;22(1):128‑40 (in Russian)]. DOI:10.21294/1814‑4861‑2023‑22‑1–128‑140
31. Kanti V, Nuwayhid R, Lindner J, et al. Analysis of quantitative changes in hair growth during treatment with chemotherapy or tamoxifen in patients with breast cancer: A cohort study. Br J Dermatol. 2014;170(3):643‑50. DOI:10.1111/bjd.12716
32. Chan J, Adderley H, Alameddine M, et al. Permanent hair loss associated with taxane chemotherapy use in breast cancer: A retrospective survey at two tertiary UK cancer centres. Eur J Cancer Care (Engl). 2021;30(3):e13395. DOI:10.1111/ecc.13395
33. Bhoyrul B, Asfour L, Lutz G, et al. Clinicopathologic characteristics and response to treatment of persistent chemotherapy-induced alopecia in breast cancer survivors. JAMA Dermatol. 2021;157(11):1335‑42. DOI:10.1001/jamadermatol.2021.3676
34. Freites-Martinez A, Shapiro J, Chan D, et al. Endocrine therapy-induced alopecia in patients with breast cancer. JAMA Dermatol. 2018;154(6):670‑5. DOI:10.1001/jamadermatol.2018.0454
35. Gallicchio L, Calhoun C, Helzlsouer KJ. Aromatase inhibitor therapy and hair loss among breast cancer survivors. Breast Cancer Res Treat. 2013;142(2):435‑43. DOI:10.1007/s10549‑013‑2744‑2
36. Rugo HS, van den Hurk C. Alopecia related to systemic cancer therapy. 2023. Available at: https://www.uptodate.com/contents/alopecia-related-to-systemic-cancer-therapy/print. Accessed: 05.09.2023.
37. Shah VV, Wikramanayake TC, DelCanto GM, et al. Scalp hypothermia as a preventative measure for chemotherapy-induced alopecia: A review of controlled clinical trials. J Eur Acad Dermatol Venereol. 2018;32(5):720‑34. DOI:10.1111/jdv.14612
38. Belum VR, de Barros Silva G, Laloni MT, et al. Cold thermal injury from cold caps used for the prevention of chemotherapy-induced alopecia. Breast Cancer Res Treat. 2016;157(2):395‑400. DOI:10.1007/s10549‑016‑3799‑7
39. Smetanay K, Junio P, Feißt M, et al. COOLHAIR: A prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer. Breast Cancer Res Treat. 2019;173(1):135‑43. DOI:10.1007/s10549‑018‑4983‑8
40. Bajpai J, Kagwade S, Chandrasekharan A, et al. Randomised controlled trial of scalp cooling for the prevention of chemotherapy induced alopecia. Breast. 2020;49:187‑93. DOI:10.1016/j.breast.2019.12.004
41. NCCN Clinical Practice Guidelines in Oncology. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx#site. Accessed: 04.11.2019.
________________________________________________
2. Lemieux J, Maunsell E, Provencher L. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: A literature review. Psychooncology. 2008;17(4):317‑28. DOI:10.1002/pon.1245
3. Trüeb RM. Chemotherapy-induced alopecia. Curr Opin Support Palliat Care. 2010;4(4):281‑4. DOI:10.1097/SPC.0b013e3283409280
4. Choi EK, Kim IR, Chang O, et al. Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients. Psychooncology. 2014;23(10):1103‑10. DOI:10.1002/pon.3531
5. Dorr VJ. A practitioner’s guide to cancer-related alopecia. Semin Oncol. 1998;25(5):562‑70. PMID:9783595
6. Auvinen PK, Mähönen UA, Soininen KM, et al. The effectiveness of a scalp cooling cap in preventing chemotherapy-induced alopecia. Tumori. 2010;96(2):271‑5. DOI:10.1177/030089161009600214
7. Hussein AM. Chemotherapy-induced alopecia: new developments. South Med J. 1993;86(5):489‑96. DOI:10.1097/00007611‑199305000‑00001
8. McGarvey EL, Baum LD, Pinkerton RC, Rogers LM. Psychological sequelae and alopecia among women with cancer. Cancer Pract. 2001;9(6):283‑9. DOI:10.1046/j.1523‑5394.2001.96007.x
9. Trüeb RM. Chemotherapy-induced hair loss. Skin Therapy Lett. 2010;15(7):5‑7. PMID: 20700552
10. Mols F, van den Hurk CJ, Vingerhoets AJ, Breed WP. Scalp cooling to prevent chemotherapy-induced hair loss: Practical and clinical considerations. Support Care Cancer. 2009;17(2):181‑9. DOI:10.1007/s00520‑008‑0475‑4
11. Paus R, Haslam IS, Sharov AA, Botchkarev VA. Pathobiology of chemotherapy-induced hair loss. Lancet Oncol. 2013;14(2):e50‑9. DOI:10.1016/S1470‑2045(12)70553‑3
12. Kang D, Kim IR, Choi EK, et al. Permanent chemotherapy-induced alopecia in patients with breast cancer: A 3‑year prospective cohort study. Oncologist. 2019;24(3):414‑20. DOI:10.1634/theoncologist.2018‑0184
13. Dunnill CJ, Al-Tameemi W, Collett A, et al. A clinical and biological guide for understanding chemotherapy-induced alopecia and its prevention. Oncologist. 2018;23(1):84‑96. DOI:10.1634/theoncologist.2017‑0263
14. Shin H, Jo SJ, Kim DH, et al. Efficacy of interventions for prevention of chemotherapy-induced alopecia: A systematic review and meta-analysis. Int J Cancer. 2015;136(5): E442‑54. DOI:10.1002/ijc.29115
15. Chon SY, Champion RW, Geddes ER, Rashid RM. Chemotherapy-induced alopecia. J Am Acad Dermatol. 2012;67(1):e37‑47. DOI:10.1016/j.jaad.2011.02.026
16. Rossi A, Caterina Fortuna M, Caro G, et al. Monitoring chemotherapy-induced alopecia with trichoscopy. J Cosmet Dermatol. 2019;18(2):575‑80. DOI:10.1111/jocd.12687
17. Freites-Martinez A, Shapiro J, Goldfarb S, et al. Hair disorders in patients with cancer. J Am Acad Dermatol. 2019;80(5):1179‑96. DOI:10.1016/j.jaad.2018.03.055
18. Haider M, Hamadah I, Almutawa A. Radiation- and chemotherapy-induced permanent alopecia: Case series. J Cutan Med Surg. 2013;17(1):55‑61. DOI:10.2310/7750.2012.12033
19. Skrok A, Bednarczuk T, Skwarek A, et al. The effect of parathyroid hormones on hair follicle physiology: Implications for treatment of chemotherapy-induced alopecia. Skin Pharmacol Physiol. 2015;28(4):213‑25. DOI:10.1159/000375319
20. Katikaneni R, Ponnapakkam T, Matsushita O, et al. Treatment and prevention of chemotherapy-induced alopecia with PTH-CBD, a collagen-targeted parathyroid hormone analog, in a non-depilated mouse model. Anticancer Drugs. 2014;25(1):30‑8. DOI:10.1097/CAD.0b013e3283650bff
21. Rugo HS, Klein P, Melin SA, et al. Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. JAMA. 2017;317(6):606‑14. DOI:10.1001/jama.2016.21038
22. Nangia J, Wang T, Osborne C, et al. Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: The SCALP randomized clinical trial. JAMA. 2017;317(6):596‑605. DOI:10.1001/jama.2016.20939
23. Trujillo-Martín MM, de Armas-Castellano A, González-Hernández Y, et al. Enfriamiento del cuero cabelludo para la prevención de la alopecia secundaria a quimioterapia: Revisión sistemática y metanálisis. Rev Esp Salud Publica. 2023;97:e202303024 (in Spanish). PMID:36999663
24. Rugo HS, Voigt J. Scalp hypothermia for preventing alopecia during chemotherapy. A systematic review and meta-analysis of randomized controlled trials. Clin Breast Cancer. 2018;18(1):19‑28. DOI:10.1016/j.clbc.2017.07.012
25. Lacouture ME, Sibaud V, Gerber PA, et al.; ESMO Guidelines Committee. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines. Ann Oncol. 2021;32(2):157‑70. DOI:10.1016/j.annonc.2020.11.005
26. Cho J, Choi EK, Kim IR, et al. Development and validation of Chemotherapy-induced Alopecia Distress Scale (CADS) for breast cancer patients. Ann Oncol. 2014;25(2):346‑51. DOI:10.1093/annonc/mdt476
27. Wilson BE, Jacob S, Yap ML, et al. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: A population-based study. Lancet Oncol. 2019;20(6):769‑80. DOI:10.1016/S1470‑2045(19)30163‑9
28. Gandhi M, Oishi K, Zubal B, Lacouture ME. Unanticipated toxicities from anticancer therapies: Survivors’ perspectives. Support Care Cancer. 2010;18(11):1461‑8. DOI:10.1007/s00520‑009‑0769‑1
29. Paterson C, Kozlovskaia M, Turner M, et al. Identifying the supportive care needs of men and women affected by chemotherapy-induced alopecia? A systematic review. J Cancer Surviv. 2021;15(1):14‑28. DOI:10.1007/s11764‑020‑00907‑6
30. Stanoevich IV, Khvostovoy VV, Tishina EI, et al. Alopecia in oncology: The practical significance of fundamental research. Siberian Journal of Oncology. 2023;22(1):128‑40 (in Russian). DOI:10.21294/1814‑4861‑2023‑22‑1–128‑140
31. Kanti V, Nuwayhid R, Lindner J, et al. Analysis of quantitative changes in hair growth during treatment with chemotherapy or tamoxifen in patients with breast cancer: A cohort study. Br J Dermatol. 2014;170(3):643‑50. DOI:10.1111/bjd.12716
32. Chan J, Adderley H, Alameddine M, et al. Permanent hair loss associated with taxane chemotherapy use in breast cancer: A retrospective survey at two tertiary UK cancer centres. Eur J Cancer Care (Engl). 2021;30(3):e13395. DOI:10.1111/ecc.13395
33. Bhoyrul B, Asfour L, Lutz G, et al. Clinicopathologic characteristics and response to treatment of persistent chemotherapy-induced alopecia in breast cancer survivors. JAMA Dermatol. 2021;157(11):1335‑42. DOI:10.1001/jamadermatol.2021.3676
34. Freites-Martinez A, Shapiro J, Chan D, et al. Endocrine therapy-induced alopecia in patients with breast cancer. JAMA Dermatol. 2018;154(6):670‑5. DOI:10.1001/jamadermatol.2018.0454
35. Gallicchio L, Calhoun C, Helzlsouer KJ. Aromatase inhibitor therapy and hair loss among breast cancer survivors. Breast Cancer Res Treat. 2013;142(2):435‑43. DOI:10.1007/s10549‑013‑2744‑2
36. Rugo HS, van den Hurk C. Alopecia related to systemic cancer therapy. 2023. Available at: https://www.uptodate.com/contents/alopecia-related-to-systemic-cancer-therapy/print. Accessed: 05.09.2023.
37. Shah VV, Wikramanayake TC, DelCanto GM, et al. Scalp hypothermia as a preventative measure for chemotherapy-induced alopecia: A review of controlled clinical trials. J Eur Acad Dermatol Venereol. 2018;32(5):720‑34. DOI:10.1111/jdv.14612
38. Belum VR, de Barros Silva G, Laloni MT, et al. Cold thermal injury from cold caps used for the prevention of chemotherapy-induced alopecia. Breast Cancer Res Treat. 2016;157(2):395‑400. DOI:10.1007/s10549‑016‑3799‑7
39. Smetanay K, Junio P, Feißt M, et al. COOLHAIR: A prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer. Breast Cancer Res Treat. 2019;173(1):135‑43. DOI:10.1007/s10549‑018‑4983‑8
40. Bajpai J, Kagwade S, Chandrasekharan A, et al. Randomised controlled trial of scalp cooling for the prevention of chemotherapy induced alopecia. Breast. 2020;49:187‑93. DOI:10.1016/j.breast.2019.12.004
41. NCCN Clinical Practice Guidelines in Oncology. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx#site. Accessed: 04.11.2019.
Авторы
Н. А. Огнерубов*1, С. В. Барсуков2,3
1Пензенский институт усовершенствования врачей – филиал ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Пенза, Россия;
2ООО «Медицинский центр “Октябрьская, 23”», Тамбов, Россия;
3ГБУЗ «Тамбовский областной онкологический клинический диспансер», Тамбов, Россия
*ognerubov_n.a@mail.ru
1Penza Institute for Advanced Training of Physicians – branch of the Russian Medical Academy of Continuous Professional Education, Penza, Russia;
2Medical Center “Oktyabrskaya, 23”, Tambov, Russia;
3Tambov Regional Oncological Clinical Dispensary, Tambov, Russia
*ognerubov_n.a@mail.ru
1Пензенский институт усовершенствования врачей – филиал ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Пенза, Россия;
2ООО «Медицинский центр “Октябрьская, 23”», Тамбов, Россия;
3ГБУЗ «Тамбовский областной онкологический клинический диспансер», Тамбов, Россия
*ognerubov_n.a@mail.ru
________________________________________________
1Penza Institute for Advanced Training of Physicians – branch of the Russian Medical Academy of Continuous Professional Education, Penza, Russia;
2Medical Center “Oktyabrskaya, 23”, Tambov, Russia;
3Tambov Regional Oncological Clinical Dispensary, Tambov, Russia
*ognerubov_n.a@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.